Early recurrence in a pooled international cohort of melanoma patients treated with adjuvant nivolumab in a real-world setting

• L. Mortier,
• R. Gutzmer,
• V. Atkinson,
• S. Dalle,
• P. Saiag,
• B. Neyns,
• A. Rorive,
• P. Parente,
• M. Weichenthal,
• J.-J. Grob,
• C. Lebbé,
• P. Mohr,
• T. Eigentler,
• L. McDonald,
• L. Willemot,
• F. Brellier,
• O. Bakharevski,
• S. Houssou,
• M. Jadhao,
• D. Schadendorf

Affiliations

L. Mortier

Lille University Hospital (*Co-lead, contributed equally), Lille, France

R. Gutzmer

Mühlenkreiskliniken (*Co-lead, contributed equally), Minden, Germany

V. Atkinson

Princess Alexandra Hospital, Woolloongabba, & Greenslopes Private Hospital, Greenslopes, Australia

S. Dalle

Lyon-Sud Hospital, Lyon, France

P. Saiag

Ambroise Paré Hospital, Boulogne-Billancourt, France

B. Neyns

Universitair Ziekenhuis Brussel, Brussels, Belgium

A. Rorive

CHU Sart Tilman de Liège, Liège, Belgium

P. Parente

Epworth Eastern, Eastern Health, Box Hill, Australia

M. Weichenthal

Universitätsklinikum Schleswig-Holstein, Kiel, Germany

J.-J. Grob

Aix-Marseille University, AP-HM, Timone, Marseille, France

C. Lebbé

Saint Louis Hospital, Paris, France

P. Mohr

Elbe-Kliniken Buxtehude, Buxtehude, Germany

T. Eigentler

Charité-Universitätsmedizin, Berlin, Germany

L. McDonald

Bristol Myers Squibb, Uxbridge, United Kingdom

L. Willemot

Bristol Myers Squibb, Braine L’Alleud, Belgium

F. Brellier

Bristol Myers Squibb, Uxbridge, United Kingdom

O. Bakharevski

Bristol Myers Squibb, Princeton, United States of America

S. Houssou

Bristol Myers Squibb, Rueil-Malmaison, France

M. Jadhao

Mu Sigma, Northbrook, United States of America

D. Schadendorf

Universitätsklinikum, Essen, Germany